2-[(2E,6E,10E,14E,18E,22E)-3,7,11,15,19,23,27-heptamethyloctacosa-2,6,10,14,18,22,26-heptaen-1-yl]-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione

• ChemBase ID: 164886
• Molecular Formular: C44H66O4
• Molecular Mass: 658.99244
• Monoisotopic Mass: 658.49611059
• SMILES: C1(=C(C(=O)C(=C(C1=O)OC)OC)C)C/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)\C)\C)\C)\C
• Canonical SMILES: COC1=C(OC)C(=O)C(=C(C1=O)C/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)\C)\C)\C)\C)C
• InChI: InChI=1S/C44H66O4/c1-32(2)18-12-19-33(3)20-13-21-34(4)22-14-23-35(5)24-15-25-36(6)26-16-27-37(7)28-17-29-38(8)30-31-40-39(9)41(45)43(47-10)44(48-11)42(40)46/h18,20,22,24,26,28,30H,12-17,19,21,23,25,27,29,31H2,1-11H3/b33-20+,34-22+,35-24+,36-26+,37-28+,38-30+
• InChIKey: DBESHHFMIFSNRV-RJYQSXAYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: 2-[(2E,6E,10E,14E,18E,22E)-3,7,11,15,19,23,27-heptamethyloctacosa-2,6,10,14,18,22,26-heptaen-1-yl]-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione
• IUPAC Traditional name: ubiquinone 7
• Synonyms: 2-[(2E,6E,10E,14E,18E,22E)-3,7,11,15,19,23,27-Heptamethyl-2,6,10,14,18,22,26-octacosaheptaenyl]-5,6-dimethoxy-3-methyl-2,5-cyclohexadiene-1,4-dione; CoQ7; UQ7; (all-E)-2-(3,7,11,15,19,23,27-Heptamethyl-2,6,10,14,18,22,26-octacosaheptaenyl)-5,6-dimethoxy-3-methyl-p-benzoquinone; Ubiquinone 35; Ubiquinone 7; Ubiquinone Q7; (all-E)-2-(3,7,11,15,19,23,27-Heptamethyl-2,6,10,14,18,22,26-octacosaheptaenyl)-5,6-dimethoxy-3-methyl-2,5-cyclohexadiene-1,4-dione; trans-Coenzyme Q7; Coenzyme Q7

Database IDs

• CAS Number: 303-95-7
• PubChem SID: 162259020
• PubChem CID: 5289540

CALCULATED PROPERTIES

• H Acceptors: 4
• H Donor: 0
• LogD (pH = 5.5): 12.176986
• LogD (pH = 7.4): 12.176986
• Log P: 12.176986
• Molar Refractivity: 215.1974 cm^3
• Polarizability: 80.49684 Å^3
• Polar Surface Area: 52.6 Å^2
• Rotatable Bonds: 22
• Lipinski's Rule of Five: false

DETAILS

Toronto Research Chemicals - C636480

An isoprenoid quinone that siginificantly reduced blood sugar and ketone bodies of diabetics. It has been shown to decrease high blood citrate level in humans with periodontal disease. It is a viable therapeutic agent for muscular dystrophy.

REFERENCES

• Shigeta, Y. et al.: J. Vitaminol., 12, 293 (1966)
• Imai, H.: Shika Igaku, 35, 530 (1966)
• Folkers, K. et al.: Int. J. Vitam. Nutrit. Res., 42, 139 (1966)